GSK shrinks Scynexis deal after delay in commercialization of antifungal drug

Scynexis will get less money in a multimillion-dollar license agreement with GlaxoSmithKline after potential cross-contamination in the manufacturing of its antifungal drug delayed commercialization.

Scynexis said in SEC filings it has already received an upfront payment of $90 million and one development milestone payment of $25 million in the deal to license ibrexafungerp, approved as Brexafemme to treat vaginal yeast infections, to GSK. GSK will also pay royalties based on annual sales, the terms of which were left unchanged.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。